Two Eli Lilly incretin compounds, one approved and one investigational. On the Research Quality Score they now sit just 9 points apart - both in the Strong Evidence band - and the entire gap comes from a single dimension: replication depth.
These two are now closer than they have ever been. Both sit in the Strong Evidence band. They tie on study design, sample size, journal quality, population diversity, and researcher pedigree - five of seven dimensions. The entire score gap collapses to replication (+8 to tirzepatide) and a negligible edge in funding independence (+1 to retatrutide, which now scores slightly better on that dimension). That is the narrowest meaningful comparison in the catalog.
The cause is straightforward: tirzepatide's evidence base is further along. It has a completed, published, independently scrutinized Phase III program and FDA approval as Mounjaro and Zepbound. Retatrutide's Phase III TRIUMPH program is still reading out, and its results have not yet been independently replicated - which is all the Replication gap reflects.
The point that matters most, and the one a score alone hides: retatrutide's lower number does not mean it works less well. Its Phase III TRIUMPH-1 readout showed roughly 28 to 30 percent mean body weight reduction, the largest reported in a Phase III obesity trial to date, exceeding tirzepatide's own SURMOUNT-1 result. The RQS grades how mature and robust the research is, not how large the effect is. Reading "91 versus 82" as "tirzepatide is the better compound" is misreading what the score measures.
One dimension worth noting: retatrutide now scores higher on Funding Independence (4 vs 3). Both are overwhelmingly Lilly-funded, but the slight difference likely reflects the composition of the trial portfolios at this point in time. Neither compound has meaningfully independent funding - this is a shared limitation of the incretin field, not a distinguishing feature of either one specifically.
So the actual decision is not "which scored higher." It is a choice between an approved compound with a mature, dispensable-today evidence base and an investigational compound with the largest reported Phase III weight loss effect on record but a younger research record that is not yet complete. That tradeoff belongs in a conversation with a clinician, not a takeaway from a number.